Tanabe Pharma America Company Profile - aVenture Research
Tanabe Pharma America
Tanabe Pharma America is the U.S. subsidiary of Japan's Tanabe Pharma Corporation, advancing rare-disease therapies including the protoporphyria candidate dersimelagon.
Tanabe Pharma America, launched in 2016 and headquartered in Jersey City, New Jersey, is the wholly-owned U.S. commercial and development subsidiary of Tanabe Pharma Corporation. The company focuses on rare and hard-to-treat conditions in the United States, drawing on the parent group's long history in central-nervous-system and rare-disease medicine.
It submitted and holds responsibility for the U.S. regulatory review of dersimelagon, an oral melanocortin-1 receptor agonist for erythropoietic and X-linked protoporphyria, whose global rights were transferred to LEO Pharma in 2026 while the U.S. NDA remains under priority review.
